CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 88 enrolled
Drug / intervention
D6-25-hydroxyvitamin D3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02937350
NCT02937350Phase 1Completed
CompareCT.gov

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

University of Washington·interventional·Posted Oct 18, 2016·Updated Sep 1, 2021

In Brief

A Phase 1 clinical trial evaluating D6-25-hydroxyvitamin D3 for Chronic Kidney Disease. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 18, 2016
Enrollment StartMar 1, 2017
Primary CompletionJul 8, 2019
Study CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.7 years ago

Interventions

D6-25-hydroxyvitamin D3drug

Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3